Data / Drug companies / Allegis Pharmaceuticals, LLC
Allegis Pharmaceuticals, LLC: 12 products in the FDA NDC directory, labeler code 28595
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Allegis Pharmaceuticals, LLC (labeler code 28595) lists 12 products in the FDA National Drug Code Directory, covering 7 finished drugs by generic name. By type: 7 prescription drugs, 5 over the counter drugs. Its main marketing category is over the counter monograph drugs. The newest product started marketing on July 29, 2026.
The request: Watch Allegis Pharmaceuticals, LLC (FDA labeler code 28595): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 28595
- Products in commercial distribution
- 12
- Packages
- 12
- Finished drugs by generic name
- 7
- Prescription products
- 7
- Over the counter products
- 5
- Flagged as original packager
- 4 of 4 products that carry the flag
- Started marketing in the last 12 months
- 2
- Products with a marketing end date set
- 2
- Earliest marketing start
- March 4, 2014
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Over the counter monograph drugs | 5 | 41.7% |
| Other unapproved drugs | 3 | 25% |
| Generic drugs (ANDA) | 2 | 16.7% |
| Authorized generics (NDA) | 2 | 16.7% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 7 | 58.3% |
| Over the counter drugs | 5 | 41.7% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Triprolidine hydrochloride | 2 | 3 |
| Ketoprofen | 1 | 5 |
| Nitroglycerin | 1 | 40 |
| Megnesium oxide | 1 | 1 |
| Sulfacetamide sodium and sulfur | 1 | 4 |
| Spinosad | 1 | 3 |
| Hydrocortisone acetate cream | 1 | 2 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Syrup | 4 | 33.3% |
| Capsule | 3 | 25% |
| Suspension | 2 | 16.7% |
| Spray | 1 | 8.3% |
| Tablet | 1 | 8.3% |
| Cream | 1 | 8.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Hydrocortisone Acetate Cream | 28595-050 | Cream | Generic drugs (ANDA) | July 29, 2026 |
| Orudis | 28595-031 | Capsule | Generic drugs (ANDA) | January 7, 2026 |
| HISTEX-DM New Formulation | 28595-310 | Syrup | Over the counter monograph drugs | March 10, 2025 |
| Mb caps | 28595-299 | Capsule | Other unapproved drugs | February 25, 2025 |
| Mag 440 | 28595-710 | Tablet | Over the counter monograph drugs | January 27, 2025 |
| Sulfacetamide sodium and sulfur Sodium Sulfacetamide - Sulfur | 28595-501 | Suspension | Other unapproved drugs | June 18, 2024 |
| HISTEX PD Drops New Formulation | 28595-809 | Syrup | Over the counter monograph drugs | December 13, 2023 |
| Urimar-t caps | 28595-224 | Capsule | Other unapproved drugs | June 28, 2023 |
| Nitroglycerin lingual | 28595-120 | Spray | Authorized generics (NDA) | July 1, 2019 |
| Spinosad | 28595-570 | Suspension | Authorized generics (NDA) | June 25, 2014 |
| Histex-dm | 28595-804 | Syrup | Over the counter monograph drugs | March 19, 2014 |
| Histex | 28595-802 | Syrup | Over the counter monograph drugs | March 4, 2014 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.